source
- InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trialInnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral…
- B. Braun pulls spinal anesthesia kits after recall of bupivacaine in dextrose injectionB. Braun Medical, Inc. has issued a recall of several spinal anesthesia convenience kits that contain Huons bupivacaine hydrochloride in dextrose injection. The recall follows a request from Huons…